CHO Platform Evaluation for Biopharmaceuticals Production

There is a high demand to develop an efficient platform for biopharmaceutical production, especially considering the fast growth of biosimilar. Chinese hamster ovary (CHO) is the most popular expression system for therapeutic proteins in the biopharmaceutical industry. However, the lack of knowledge of a systematic evaluation and comparison of various CHO systems might hamper the production of recombinant proteins. In this study, we used biosimilar as a model protein to evaluate different expression vectors (dhfr and GS), CHO host cells (i.e., CHO K1, CHO DG44, and CHO S), and commercial CHO media. The stable cell line development using different systems was also compared, including transfection, amplification and single cell cloning. In addition, advanced Omics technology was applied to identify the regulator candidates, which are being used to construct a novel engineered CHO host cell. In the future, an efficient CHO platform will be created to achieve high production, high quality and high stability in biopharmaceuticals production.